CONCLUSIONS
Overall, our study findings suggest that patients with a history of cancer who are hospitalized with SARS-CoV-2 are not at greater risk for AKI, though they are at higher risk for mortality as compared to hospitalized patients without a cancer diagnosis. The increased risk in mortality appears driven by patients with pulmonary neoplasms. Patients with genitourinary malignancies do not appear to be at higher risk for mortality or for AKI compared to those without malignancy.
This finding is of great clinical importance as we navigate the “new-normal” phase of the COVID19 pandemic. Healthcare providers must guide patients through weighing the risks of delaying therapy against the risks of contracting COVID19 in the nosocomial setting. Understanding that the risk of adverse outcomes in patients with histories of genitourinary malignancy is similar to that of the general public may help guide patients through this challenging and anxiety provoking risk-benefit analysis. Further study with a larger cohort of genitourinary malignancy patients in a prospective manner is warranted.